The stability of free and bound prostate-specific antigen

BJU International

Volumn 84, Issue 7, 1999, Pages 810-814

  Cartledge, J J ^a   Thompson, D ^a   Verril, H ^b   Clarkson, P ^a   Eardley, I ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Assay; Free; Prostate specific antigen; Stability; Total

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ARTICLE; BLOOD; BLOOD STORAGE; CENTRIFUGE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVICE; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; LABORATORY TEST; MALE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SERUM; TEMPERATURE;

HUMANS; IMMUNOENZYME TECHNIQUES; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 0032706167     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1999.00311.x     Document Type: Article

References (25)

1. 1 Wang MC, Valenzula LA, Murphy GP, Chu TM. Purification of a human prostate-specific antigen. Invest Urol 1979; 17: 159-63
2. 2 Papsidero LD, Kuriyama M, Wang MC et al. Prostate antigen: a marker for human prostate epithelial cells. J Nat Canc Inst 1981; 48: 1229-32
3. 3 Papsidero LD, Wang MC, Valenzula LA, Murphy GP, Chu TM. A prostate antigen in sera of prostatic cancer patients. Cancer Res 1980; 40: 2428
4. 4 Brawer MK, Lange PH. Prostate specific antigen: its role in early detection, staging, and monitoring of prostatic carcinoma. J Endourol 1989; 3: 227-36
5. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
6. 1-antichymotrypsin in blood. J Urol 1993; 149: 332
7. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5
8. 8 van Jersel MP, Witjes WPJ. Thomas CMG, Segers MFG, Oosterhof GON, Debruyne FMJ. Review of the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. Prostate 1996; 7: 48-57
9. 9 Catalona WJ. Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate 1996; 7: 64-9
10. 10 Smith DS, Catalona WJ. Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276: 1309-15
11. 11 Benson MC, Whang IS, Olsson CA, McMahon DJ. Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate-specific antigen. J Urol 1992; 147: 817-21
12. 12 Oesterling JE. Jacobsen SJ. Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age specific reference ranges. JAMA 1993; 270: 860-4
13. 13 Luderer AA, Chen Y-T, Soriano TF et al. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 1995; 46: 187-94
14. 14 Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20
15. 15 Morgan TO, McLeod DG, Leifer ES, Moul JVV, Murphy GP. Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. Prostate 1996; 7: 58-63
16. 16 van Cangh PJ, de Nayer P, Sauvage P et al. Free to total prostate-specific antigen (PSA) is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate 1996; 7: 30-4
17. 17 Vashi AR, Wojno KJ, Henricks W et al. Determination of the 'reflex range' and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997; 49: 19-27
18. 18 Schifman RB, Ahmann FR, Elvick A, Ahmann M, Coulis K, Brawer MK. Analytical and physiological characteristics of prostate-specific antigen and prostatic acid phosphatase in serum compared. Clin Chem 1987; 33: 2086-8
19. 19 Simm B, Gleeson M. Storage conditions for serum for estimating prostate-specific antigen. Clin Chem 1991; 37: 113-4
20. 20 Jacobsen SJ, Klee GG, Lilja H, Wright GL, Oesterling JE. Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. Urology 1995; 45: 447-53
21. 21 Jung K, von Klinggraff P, Brux B, Sinha P, Schnorr D, Loenig SA. Preanalytical determinants of total and free prostate-specific antigen and their ratio: blood collection and storage conditions. Clin Chem 1998; 44: 685-8
22. 22 Cuny C, Pham L, Kramp W, Sharp T, Soriano TF. Evaluation of a two-site immunoradiometric assay for measuring noncomplexed (free) prostate-specific antigen. Clin Chem 1996; 42: 1243-9
23. 1,-antichymotrypsin complex. Clin Chem 1995; 41: 1480-8
24. 24 Arcangeli CG, Smith DS, Ratliff TL, Catalona WJ. Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol 1997; 158: 2182-7
25. 25 Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and storage conditions. Urology 1996; 48: 33-9